We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA to Replace Guidance on Developing New Pain Drugs
FDA to Replace Guidance on Developing New Pain Drugs
FDA Commissioner Scott Gottlieb said the agency plans to scrap its existing guidance on developing new pain drugs and replace it with guidances designed to promote development of new opioid alternatives and improve benefit and risk assessments of new opioid drugs in the works. “Everything is on the table,” Gottlieb said in announcing the move aimed at driving innovation for fresh options to the potent, addictive pain meds. He noted the initiative will include at least four new guidances.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor